Composition
- Active ingredients
- CEFPODOXIME PROXETIL EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- CEFPODOXIME PROXETIL EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA050674-001 · Discontinued
- CEFPODOXIME PROXETIL EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletThis page
- CEFPODOXIME PROXETIL EQ 50MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · For suspensionNDA050675-001 · Discontinued
- CEFPODOXIME PROXETIL EQ 100MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · For suspensionNDA050675-002 · Discontinued
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA050674.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Vantin
- Active substance
- cefpodoxime proxetil
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Pfizer
- Status
- Discontinued
- FDA approval
- 7 Aug 1992
- Application
- NDA050674-002